Search

Displaying results 171 - 180 of 489 in total
  1. Drug

    Sevabertinib

    go.drugbank.com/drugs/DB21667
    ApprovedInvestigational

    Sevabertinib is a kinase inhibitor indicated for adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations. Sevaber...

  2. Drug

    Eslicarbazepine acetate

    go.drugbank.com/drugs/DB09119
    ApprovedInvestigational

    Eslicarbazepine acetate (ESL) is an anticonvulsant medication approved for use in Europe, the United States and Canada as an adjunctive therapy for partial-onset seizures that are not adequately controlled … Eslicarbazepine acetate is marketed as Aptiom in North America and Zebinix or Exalief in Europe. It is available in 200, 400, 600, or 800mg tablets that are taken once daily, with or without food.

  3. Drug

    Elacestrant

    go.drugbank.com/drugs/DB06374
    ApprovedInvestigational

    Elacestrant is a non-steroidal small molecule and an estrogen receptor (ER) antagonist. In January 2023, it was approved by the FDA for the treatment of ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer. It re...

  4. Drug

    Ertapenem

    go.drugbank.com/drugs/DB00303
    ApprovedInvestigational

    [L14339] It was first authorized for use in the US in November 2001 and in Europe in April 2002.

  5. Drug

    TSHA-118

    go.drugbank.com/drugs/DB16996
    Experimental

    TSHA-118 is a self-complementary AAV9 gene replacement therapy designed to express a human codon-optimized CLN1 transgene for the treatment of CLN1 disease.

  6. Drug

    KT-A261

    go.drugbank.com/drugs/DB19317
    Experimental

    KT-A261 is an adeno-associated viral vector serotype 2 (AAV2) encoded to express adalimumab. It is being investigated for the treatment of noninfectious uveitis.

  7. Drug

    AVXS-301

    go.drugbank.com/drugs/DB17943
    Experimental

    AVXS-301 consists of an adeno-associated virus serotype 9 (AAV9) designed to express the superoxide dismutase 1 (SOD1) gene.

  8. Drug

    Tislelizumab

    go.drugbank.com/drugs/DB14922
    ApprovedInvestigational

    Tislelizumab is a humanized monoclonal IgG4 antibody against programmed death receptor-1 (PD-1). It was engineered to have a nullified Fc portion, thus minimizing binding to FcγR on macrophages and limiting treatment resistance via antib...

  9. Drug

    Futibatinib

    go.drugbank.com/drugs/DB15149
    ApprovedInvestigational

    [L43347] On July 4, 2023, the European Commission granted Conditional Marketing Authorization for futibatinib for the treatment of cholangiocarcinoma.[L47800]

  10. Drug

    Blinatumomab

    go.drugbank.com/drugs/DB09052
    ApprovedInvestigational

    [A254836,L44311] CD3 is an antigen expressed on the surface of T-cells, while CD19 is mostly expressed on the surface of malignant B-cells.